Over the last few years, the incidence of therapy-related tumors has increased considerably. This implies a serious problem as they often do not respond to conventional treatments and have a worse evolution than de novo-cases. Therefore, understanding their origin, risk and functioning is key to future diagnoses and treatments. In this article, researchers evaluated if genetic variants in two genes of the p53 pathway (TP53 and MDM2) can be related to therapy-related myeloid neoplasms.
|Translated title of the contribution||Possible MDM2 and TP53 genes involvement in the risk of Developing Therapy-Related Myeloid Neoplasms|
|Number of pages||3|
|Publication status||Published - 2019|